Arch Biopartners Announces Issuance of Additional U.S. Patent for Biofilm Inhibitor
TORONTO, ONTARIO--(Marketwired - June 6, 2013) - Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH) (OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued an additional patent for an invention preventing or inhibiting the growth of biofilm formation on surfaces.
This patent is based on technology invented at the University of Colorado and the University of Alberta and is exclusively licensed to Arch.
The newly issued U.S. patent entitled "Non-toxic biofilm inhibitor" considerably broadens the claims of the biofilm patent licensed to Arch and issued in July, 2011, by expanding both the utility of this technology and the number of compounds that can be used to minimize biofilm formation.
Biofilms are the growth and colonization of bacteria on a surface. They constitute a significant problem in the healthcare environment, causing a wide range of medical device-associated infections in patients.
Biofilm is also a problem in the industrial setting and is a major contributing factor to corrosion.
Arch believes that this technology represents a potential platform that addresses large unmet needs in industry and in healthcare. Arch continues to validate this technology in the areas of decreasing corrosion on metals and inhibiting bacteria attachment to plastic and metal surfaces.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.